Washington: US researchers have warned, Donepezil, a medication that is approved to treat people with Alzheimer’s disease, should not be prescribed for people with mild cognitive impairment, without a genetic test.
Researchers from the University Of California discovered that for people who carry a specific genetic variation, the K-variant of butyrylcholinesterase, or BChE-K donezpezil, could accelerate cognitive decline.
The study has been published in Journal of Alzheimer’s Disease.
Mild cognitive impairment is a transitional state between normal age-related changes in cognition and dementia.
Because many people with the condition display symptoms similar to those caused by Alzheimer’s disease, some physicians prescribe donepezil, which is marketed under the brand name
Donepezil was tested as a possible treatment for mild cognitive impairment in a large, federally funded study published in 2005, but it was not approved by the FDA.
Still, doctors have often prescribed the drug “off-label” — meaning that it is not approved for that specific disorder — for their patients with mild cognitive impairment.
The researchers looked at the association between BChE-K and changes in cognitive function. Using two tests that measure cognitive impairment, the Mini-Mental State Examination and the Clinical Dementia Rating Sum of Boxes.
The findings indicated that people with the genetic variation, who were treated with donepezil had greater changes in their scores than those who took placebos.
They also found that those who took donepezil had a faster cognitive decline than those who took the placebo.
The findings reinforce the importance of physicians discussing the possible benefits and risks of this treatment with their patients.